VetMedGuide

Vet Med Guide

A clinical pharmacy counter with folders, empty vials, and a clipboard tracking drug inventory backorders under soft warm light.
Practice2026-07-15 · 22 min read

Veterinary Drug Shortages: Substitution, Compounding, and Client SOPs

An operational playbook for handling veterinary drug backorders. Check the FDA list, evaluate MNVPs, choose safe substitutes, compound under GFI #256, and manage client SOPs.

Ran Chen
Ran Chen
Founder, VetMedGuide. Life-sciences operator and 10× global market-access lead.
Published

Drug backorders and supply chain failures have become a persistent challenge in veterinary practice. When a critical therapeutic agent goes out of stock, it is not merely an inventory headache—it is a clinical and operational emergency. A clinic’s response to a shortage must balance regulatory boundaries, patient safety, clinical efficacy, and client communication. Improvising a substitute without a systematic workflow can lead to dosing errors, therapeutic failures, regulatory non-compliance, or compromised patient care.

Developing a resilient operational playbook allows veterinary practice owners, medical directors, and inventory managers to make structured, evidence-based decisions when essential drugs are backordered. This guide outlines how to determine a drug's official shortage status, identify high-stakes medications with no direct alternatives, safely evaluate therapeutic substitutes by drug class, utilize legal compounding pathways under FDA Guidance for Industry (GFI) #256, and communicate these changes to pet owners.

Is my drug actually on the FDA veterinary shortage list, and does that matter?

The first step when a supplier reports a stockout is to verify whether the shortage is localized, regional, or an officially recognized national supply failure. In the United States, the Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) maintains the official "Current and Resolved Animal Drug Shortages" list.

Under the Federal Food, Drug, and Cosmetic Act, the FDA CVM monitors the supply of approved animal drugs. However, the agency does not have the legal authority to compel any manufacturer to produce a drug, speed up production, or distribute a product. The CVM's role is to coordinate with sponsors to address the root causes of the shortage, evaluate regulatory flexibility (such as allowing temporary importation or extending expiration dates), and maintain public communication.

A key concept within this framework is the Medically Necessary Veterinary Product (MNVP). An MNVP is defined as an animal drug product used to treat or prevent a serious disease or condition, or a product for which there is no other drug approved in the United States that is an adequate substitute. When an MNVP is in short supply, the FDA CVM initiates active mitigation plans, working closely with the manufacturer to resolve raw material shortages, manufacturing facility issues, or regulatory delays.

Knowing whether a backordered drug is on the FDA list matters for three critical operational reasons:

  1. Compounding Legality: The FDA CVM enforces compounding rules under compounding under FDA GFI 256. Under normal circumstances, compounding a drug that is essentially a copy of an approved, commercially available animal drug is prohibited. However, when an approved animal drug is on the FDA CVM's active shortage list, the FDA allows pharmacies to compound the drug from bulk substances under enforcement discretion, provided all other GFI #256 conditions are met.
  2. Clinical Horizon Planning: The FDA shortage list provides official status updates, including estimated resolution timelines. This information is vital for veterinary inventory reorder workflow adjustments, allowing clinics to estimate how long they must stretch their current buffer stock.
  3. Sourcing Alternatives: If a drug is not on the official list, the shortage may be a localized distribution bottleneck. Before changing protocols, the inventory lead should contact alternative distributors, check manufacturer-direct stock programs, or look for available inventory at sister practices.

To report a new animal drug shortage or check the active list, clinics can email the FDA CVM drug shortage team at AnimalDrugShortages@fda.hhs.gov. Note that vaccine shortages are not managed by the FDA; instead, they are monitored by the USDA APHIS Center for Veterinary Biologics (CVB).

Using the FDA Green Book to Find Generic Alternatives

Before concluding that a backorder requires a therapeutic substitution (switching to a different drug class), clinics should check if a generic equivalent exists. The FDA CVM publishes the Approved Animal Drug Products database, commonly known as the Green Book.

The Green Book lists all approved New Animal Drug Applications (NADAs) and Abbreviated New Animal Drug Applications (ANADAs) for generic versions. By searching the Green Book by active ingredient or NADA number, inventory managers can identify if other manufacturers hold approvals for the same drug. For example, if brand-name carprofen (Rimadyl) is backordered, the Green Book lists multiple approved generic ANADAs (such as Novox or Carprofen Chewables). Sourcing these approved generics is always clinically and legally preferred over compounding or class switching.

Which shortages are highest-stakes because there is no real substitute?

Some shortages are manageable because therapeutic alternatives within the same drug class are readily available (for example, switching from one generic cephalosporin to another). Other shortages, however, involve unique chemical entities or formulations with no approved, biologically equivalent alternatives. These high-stakes shortages threaten patient lives and require immediate, active clinical management.

Historically, several critical MNVPs have experienced severe supply disruptions, leaving clinics with few options:

  • Melarsomine Dihydrochloride (Immiticide / Diroban): The only FDA-approved heartworm adulticide. When melarsomine is backordered, clinics cannot substitute another drug class to kill adult heartworms.
  • Porcine Insulin Zinc Suspension (Vetsulin / Caninsulin): A cornerstone of feline and canine diabetes management. Diabetic stabilization is highly patient-specific, and sudden changes in insulin source can lead to life-threatening diabetic ketoacidosis (DKA) or severe hypoglycemia.
  • Desoxycorticosterone Pivalate (Percorten-V / Zycortal): An injectable mineralocorticoid (DOCP) essential for treating dogs with hypoadrenocorticism (Addison's disease).
  • Pimobendan (Vetmedin): An inodilator critical for managing congestive heart failure secondary to myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM) in dogs.

To understand the scale of these high-stakes drugs, we can look at the volume of historical data in the FDA's passive surveillance system. In the openFDA animal adverse-event database, these historically shortage-prone agents represent some of the largest reporting footprints in the life-sciences registry. Because these drugs are used chronically in high-risk patients, any disruption or protocol change carries a substantial monitoring burden.

Below is an extraction of total ingredient-mention counts within the openFDA adverse-event dimension (as of July 2026). These figures reflect the absolute frequency of drug mentions in adverse-event files, illustrating the massive clinical footprint and potential monitoring exposure associated with these critical agents:

Active Ingredient Token Total Mentions in openFDA Event Registry Clinical Context & Shortage Stakes
Melarsomine Dihydrochloride 17,018 (plus 5,106 Injection; 942 plain; 611 25mg/mL) Extreme Stakes: Heartworm adulticide. No substitute approved. Summary details show high toxicity profile if misdosed.
Pimobendan 6,325 (plus 227 Vetmedin chewable token) High Stakes: Chronic canine congestive heart failure. Sudden cessation leads to rapid decompensation and acute pulmonary edema.
Insulin Injectable Vial 5,153 (plus 2,117 Porcine Insulin) High Stakes: Diabetic regulation. Switching requires serial blood glucose curves or continuous glucose monitoring (CGM).
Desoxycorticosterone Pivalate 2,493 High Stakes: Addisonian crisis prevention. Requires close monitoring of sodium-to-potassium ratios post-switch.
Mirtazapine 2,793 (plus 26 transdermal ointment) Moderate Stakes: Feline appetite stimulation. Shortage requires transition to alternative ghrelin receptor agonists (capromorelin).
Methimazole 1,179 (plus 18 transdermal) Moderate Stakes: Feline hyperthyroidism. Shortage requires switching between oral, transdermal, or dietary options.
Potassium Bromide 517 Moderate-High Stakes: Refractory epilepsy. Long half-life makes switching to alternative anticonvulsants complex.
Cisapride 147 Moderate Stakes: GI prokinetic for feline megacolon. Must be compounded as no approved commercial option exists.
Apomorphine 132 Moderate Stakes: Emetic agent. Alternatives include dexmedetomidine (cats) or hydrogen peroxide (emergency home use, though less safe).
Sotalol 64 High Stakes: Ventricular arrhythmias. Sudden stockout requires transition to beta-blockers or amiodarone under ECG tracking.
Levamisole 165 Moderate Stakes: Agricultural/exotic dewormer. Rare shortages require transition to alternative anthelmintics.

Data Source: openFDA Animal Adverse Event Database (2026Q2 Probe). Mention counts represent active ingredient citations within adverse-event filings and do not imply direct product causality or incidence rates due to reporting biases. Denominator: 22,231 distinct active ingredients.

When these specific agents face supply chain disruptions, clinics must follow a strict triage and monitoring protocol rather than making casual substitutions.

What is the safest substitute by drug class, and what do I monitor when I switch?

When a drug goes on backorder, clinicians must evaluate the therapeutic class and choose the safest substitution pathway. These decisions fall into four main strategy categories:

[Shortage Identified]
       │
       ├─► Same Active Ingredient? (Different brand, size, concentration, or human extra-label)
       │     └─► YES: Use same ingredient. Adjust volume/dosing calculations.
       │
       ├─► Therapeutic Class Alternative? (e.g., NSAIDs, ACE inhibitors, Anticonvulsants)
       │     └─► YES: Perform class transition. Schedule monitoring for efficacy/adverse events.
       │
       ├─► No Direct Equivalent? (Melarsomine, DOCP, Insulin)
       │     └─► YES: Apply delay, staging, or legal compounding under GFI #256.
       │
       └─► Antimicrobial?
             └─► YES: Perform culture-directed selection. Do not default to broad-spectrum.

1. Endocrine and Metabolic Regulators (Insulin, DOCP, Methimazole)

Endocrine therapies are finely balanced. A switch in brand, species origin, or delivery vehicle requires immediate clinical monitoring.

  • Porcine Insulin (Vetsulin): If porcine insulin zinc suspension is backordered, canine patients cannot easily swap to human recombinant insulins without intensive re-regulation. Dogs may be transitioned to NPH insulin, but this requires an immediate 10–20% dose reduction as a safety margin, followed by a blood glucose curve 5–7 days later. Cats can be transitioned to glargine (Lantus) or detemir (Levemir), which often provides superior long-term glycemic control but requires close monitoring for hypoglycemia during the transition phase.
    • Critical Safety Warning: Syringe Conversion Factor: Vetsulin is a U-40 insulin (40 units/mL) and requires U-40 syringes. Human insulins (like NPH or Lantus) are U-100 insulins (100 units/mL) and require U-100 syringes. If a clinic switches a diabetic pet from Vetsulin to a human insulin, the owner must be provided with U-100 syringes and receive detailed re-training. Using a U-40 syringe with a U-100 insulin will result in a 2.5-fold overdose, which can cause fatal hypoglycemic shock.
  • DOCP (Zycortal/Percorten-V): If injectable DOCP is unavailable, the only approved alternative is oral fludrocortisone acetate (Florinef). Unlike DOCP, which is a pure mineralocorticoid, fludrocortisone has significant glucocorticoid activity. Vets must stop daily prednisone/prednisolone when starting fludrocortisone to avoid iatrogenic Cushing's syndrome. Electrolytes (sodium and potassium) must be checked at day 7, 14, and 30 post-transition to ensure the patient does not slide into an Addisonian crisis.
  • Methimazole: If oral methimazole is backordered, clinics can readily substitute transdermal methimazole compounded in a pluronic lecithin organogel (PLO) base, or transition the cat to a prescription iodine-restricted diet (Hill's y/d). Total T4 should be re-evaluated 2–4 weeks after any formulation switch.

2. Cardiovascular Support (Pimobendan, Sotalol, Furosemide)

  • Pimobendan: No other approved inodilator exists. In a severe shortage, clinics must ration their remaining stock for patients in active congestive heart failure (ACVIM Stage C and D) rather than using it for preclinical cardiomegaly (Stage B2). If stock is completely exhausted, veterinary-specific compounding under GFI #256 is the legal recourse.
  • Sotalol: If unavailable, transition the patient to atenolol or carvedilol. Because these beta-blockers lack sotalol's Class III antiarrhythmic properties, a follow-up 24-hour Holter monitor or clinic ECG is necessary within 10–14 days to confirm ventricular ectopy is controlled.

3. Anticonvulsant Shortages: Managing Epilepsy Transitions

Anticonvulsants are narrow therapeutic index drugs where sudden changes in serum concentrations can lead to cluster seizures or status epilepticus.

  • Phenobarbital: A primary maintenance anticonvulsant in dogs and cats. If phenobarbital tablets are backordered, the first choice is to source FDA-approved human generic phenobarbital tablets, which are bioequivalent and legal to use extra-label. If all commercial tablets are unavailable, potassium bromide (KBr) can be used as a monotherapy or adjunct in dogs, but it has a very long half-life (around 24 days), requiring a loading dose protocol to achieve therapeutic levels quickly. Alternatively, levetiracetam (Keppra) can be introduced. Levetiracetam requires frequent dosing (three times daily for immediate release), making compliance a challenge for owners. Therapeutic drug monitoring (TDM) should be performed 14 days after starting phenobarbital or 3 months after starting KBr to verify therapeutic levels and monitor for hepatotoxicity (phenobarbital) or bromide toxicity.
  • Potassium Bromide (KBr): Note that KBr must never be used in cats, as it causes a high rate of severe, life-threatening allergic pneumonitis (similar to asthma). For cats requiring alternatives to phenobarbital, levetiracetam or zonisamide are the preferred clinical options.

4. Pain Management (NSAIDs and Analgesics)

  • NSAIDs (Carprofen, Meloxicam, Deracoxib, Robenacoxib): If a specific NSAID is backordered, switching to another approved agent in the same class is generally safe but requires a "washout period" to protect the gastrointestinal tract and kidneys. When transitioning a dog from one NSAID (e.g., carprofen) to another (e.g., meloxicam or Galliprant), a 3- to 5-day washout period is clinically recommended. If transitioning from an NSAID to a corticosteroid (or vice versa), a minimum 7-day washout is mandatory due to the high risk of gastrointestinal ulceration and perforation. During the washout, pain should be managed with non-NSAID adjuncts like gabapentin, tramadol, or amantadine.

5. Heartworm Adulticides (Melarsomine Dihydrochloride)

When melarsomine is unavailable, there is no approved drug substitute that can kill adult heartworms. In this scenario, clinics must follow the American Heartworm Society (AHS) shortage guidelines:

  • Delay/Staging Strategy: For stable, asymptomatic dogs (AHS Class 1 or early Class 2), it is safer to delay the melarsomine injections by 2–3 months while maintaining the dog on strict exercise restriction and monthly macrocyclic lactone preventives.
  • The "Slow-Kill" Salvage Protocol: This method should only be used as a last resort when adulticide therapy is completely unavailable or contraindicated. It involves combining a monthly topical moxidectin preventive with a 4-week course of doxycycline (prescribed twice daily) to eliminate Wolbachia bacteria, which weakens the adult worms. However, this method takes 12–24 months to kill adult heartworms, during which time pulmonary vascular damage and pathology continue to progress.

When can a clinic legally compound during a shortage under FDA GFI #256?

Veterinary compounding is highly regulated. In April 2022, the FDA released its finalized Guidance for Industry (GFI) #256, "Compounding Animal Drugs from Bulk Drug Substances." This document outlines the circumstances under which the FDA CVM intends to exercise enforcement discretion regarding the compounding of animal drugs from raw active pharmaceutical ingredients (bulk drug substances) rather than FDA-approved products.

Under GFI #256, several key rules apply to shortage-driven compounding:

  1. No Compounding from Bulk if an Approved Product is Available: You cannot compound a drug from bulk chemical powders if there is an approved animal or human drug that can be used to meet the patient’s clinical need. For example, you cannot compound oral liquid enrofloxacin from bulk powder if commercial enrofloxacin tablets are available and can be crushed or dissolved for the patient.
  2. Shortage Exception: If the FDA-approved animal drug is on the FDA CVM's active shortage list, the FDA allows compounding from bulk drug substances to fill the gap. The pharmacy must verify that the drug is listed on the FDA’s Current Animal Drug Shortages page.
  3. Office Stock limits: Clinics may order compounded drugs from bulk substances as "office stock" only if the drug is on the CVM's list of bulk drug substances allowed for office stock (List 1). If a shortage occurs for a drug not on List 1, the clinic cannot order it as office stock; instead, they must write a patient-specific prescription to a compounding pharmacy under a valid Veterinarian-Client-Patient Relationship (VCPR).
  4. Human vs. Animal Drug Shortages: If a human-approved drug that vets use extra-label (such as sotalol or cisapride) goes on shortage, the FDA CVM coordinates with the Center for Drug Evaluation and Research (CDER). Compounding pharmacies may compound the drug from bulk, but the veterinarian must document the clinical reason why an approved animal drug cannot meet the patient's needs.

When selecting a compounding partner during a shortage, the practice manager should follow the veterinary compounding pharmacy selection fda gfi 256 audit process. Ensure the pharmacy is licensed in your state, complies with PCAB (Pharmacy Compounding Accreditation Board) standards, and explicitly labels the product as compounded without FDA approval.

Shortage Preparedness: An Inventory Management SOP

To prevent shortages from causing panic and therapeutic failure, clinics should adopt a proactive inventory forecasting and preparedness SOP. Practice managers and inventory leads should implement the following protocols:

1. Calculating Reorder Points and Safety Stock

Relying on simple visual cues to reorder drugs is a primary cause of stockouts. Inventory leads should calculate the Reorder Point (ROP) and Safety Stock (SS) using standard logistics formulas:

Reorder Point (ROP) = (Average Daily Demand × Lead Time in Days) + Safety Stock

Safety Stock (SS) = Z × √[ (Lead Time × σd²) + (Average Daily Demand² × σLT²) ]

Where:

  • Z is the service level factor — typically 1.65 for a 95% confidence level, meaning the clinic will only run out of stock about 5% of the time.
  • σd is the standard deviation of daily demand.
  • σLT is the standard deviation of supplier lead time.

For high-stakes MNVPs (like pimobendan or insulin), the service level factor (Z) should be increased to 2.33 (99% confidence level). This increases the safety stock buffer, protecting the clinic against sudden supplier backorders.

2. Sourcing Diversification

Never rely on a single primary distributor. The inventory SOP should mandate secondary and tertiary supplier accounts. For critical drugs, keep a pre-negotiated direct purchase agreement with the manufacturer. Manufacturers often maintain emergency reserves of MNVPs that they will ship directly to clinics in urgent cases, bypassing normal distributor backorders.

When facing a severe drug shortage, inventory leads may find expired or nearing-expiration bottles of the backordered drug in their pharmacy cabinets. The temptation to use these products is high, but the legal and clinical risks are severe.

1. The Ban on Unilateral Use of Expired Medications

Under U.S. federal and state laws, it is illegal for a veterinarian to dispense or administer expired medications. Doing so violates the state veterinary practice act, compromises the VCPR, and exposes the clinic to severe liability and malpractice claims if a patient experiences an adverse event or therapeutic failure. Over time, chemical active ingredients degrade, decreasing potency and, in some cases, breaking down into toxic metabolites (for example, degraded tetracycline can cause renal Fanconi syndrome).

2. The Shelf Life Extension Program (SLEP)

The FDA, in partnership with the Department of Defense, operates the Shelf Life Extension Program (SLEP). Under this program, the FDA conducts scientific stability testing on specific stockpiled drugs to determine if their expiration dates can be safely extended during national emergencies or severe shortages.

When a critical animal drug shortage occurs, the FDA CVM may coordinate with manufacturers to officially authorize the use of specific lots beyond their printed expiration dates. Crucially, clinics cannot make this determination themselves. A clinic may only use a lot beyond its expiration date if the FDA CVM has published an official notice listing that specific product, manufacturer, and lot number as eligible for extension. The inventory manager must print and file the official FDA extension notice alongside the drug log as regulatory proof during audits.

PIMS Integration and Inventory Warning Workflows

During a shortage, the Practice Management Information System (PIMS) serves as the primary tool to prevent clinical errors. When a drug is placed on backorder, the PIMS administrator should configure the system with three specific safety checkpoints:

  • Order Override Alerts: Deactivate automatic refill features in the PIMS for the backordered drug. Replace it with an interactive pop-up warning that triggers whenever a clinician attempts to add the drug to a patient treatment sheet. This alert should point directly to the medical director's approved substitution protocol.
  • Clinical Reminders for Post-Switch Monitoring: Configure the system to automatically generate a follow-up laboratory check-in task in the patient file whenever a substitute is dispensed. For example, if a patient is switched from Vetsulin to NPH insulin, the PIMS must automatically flag a task to schedule a blood glucose curve in 7 days.
  • Inventory Level Locking: Lock the inventory count in the system for critical backordered items. This prevents staff from accidentally selling reserved emergency safety stock (such as pimobendan for active Stage C patients) to non-critical patients.

What do I tell the client, and how do I avoid an antimicrobial-stewardship mistake?

The Antimicrobial Stewardship Trap

One of the most dangerous consequences of drug shortages is the temptation to compromise antimicrobial stewardship program principles. When first-line, narrow-spectrum antibiotics (like cephalexin or amoxicillin) are backordered, busy clinicians often default to whatever is on the shelf—frequently broad-spectrum, high-priority fluoroquinolones (like enrofloxacin) or third-generation cephalosporins (like Convenia).

This substitution pattern accelerates the development of antibiotic resistant bacteria dogs. To prevent this, the clinic's medical director should establish a strict substitution hierarchy for antibiotic shortages:

Backordered First-Line Agent Unacceptable Default (Avoid) Acceptable Steward-Safe Alternative
Amoxicillin / Cephalexin (Skin/UTI) Enrofloxacin (Baytril), Cefovecin (Convenia) Clindamycin, Amoxicillin-Clavulanate, Trimethoprim-Sulfa (TMPS)
Doxycycline (Lyme/Respiratory) Pradofloxacin (Veraflox) Minocycline (similar dosing and efficacy for rickettsial agents)
Metronidazole (Acute GI) Injectable Fluoroquinolones Dietary therapy, probiotics, or tylosin tartrate

Note: Always base alternative selections on culture and sensitivity testing where clinically feasible, particularly for recurrent urinary tract infections or deep pyodermas.

When a patient’s medication protocol changes due to a supply failure, the front-desk and clinical teams must handle client communication proactively to maintain trust and ensure compliance.

  • Explain the "Why" Clearly: Inform the owner that the manufacturer is experiencing a national supply disruption. Reassure them that the FDA is actively working to resolve the shortage, and that the clinic has selected a clinically appropriate alternative.
  • Provide Written Instructions: A change in pill size, concentration, or dosing frequency is a major source of medication errors. Always provide updated veterinary client communication sheets detailing the new volume, frequency, and administration instructions.
  • Detail New Monitoring Requirements: If the switch requires a follow-up blood draw or blood pressure check (e.g., after changing insulin or Addison’s medication), explain this cost and timeline upfront. Emphasize that monitoring is necessary to prevent adverse events or therapeutic failure.
  • Obtain Signed Extra-Label Consent: Prescribing human drugs or compounded bulk formulations represents extra-label drug use (ELDU). To protect the practice, the team should have the client sign an ELDU consent form, confirming they understand:
    1. The approved animal drug is currently unavailable due to a national shortage.
    2. The prescribed alternative is a compounded bulk substance or a human-labeled medication.
    3. The alternative has not undergone the same FDA approval process for this species, but is selected as the safest clinical substitute.
  • Manage Pricing Discrepancies: Compounded drugs or human extra-label alternatives may be significantly more expensive than the standard approved animal drug. If the cost rises, provide the client with written options, including writing a prescription to a human retail pharmacy (using discount cards like GoodRx) or discussing payment options via your veterinary payment plan workflow.

SOP Checklist for Shortage Response

To ensure the clinical and inventory teams act in unison, practice owners should implement this standard operating procedure when a drug is backordered:

  1. Verify Shortage: Inventory manager checks alternative distributors. If unavailable nationwide, verify if the drug is on the FDA CVM shortage list.
  2. Flag MNVP Status: Determine if the drug is an MNVP. If yes, notify the medical director immediately to evaluate rationing or alternative sourcing.
  3. Draft Clinical Protocol: Medical director writes a brief protocol specifying:
    • Approved therapeutic alternatives.
    • Required washout periods.
    • Post-switch monitoring schedules (dates and lab codes).
  4. Update PIMS: Update the Practice Management Information System (PIMS) to flag the backordered item and link the clinical substitution protocol to the patient file.
  5. Brief CSRs and Techs: Hold a short team huddle to review client communication scripts, pricing adjustments, and medication safety warnings.

By establishing these steps beforehand, clinics can protect patient health, maintain regulatory compliance, and reduce team stress during supply disruptions.

Frequently Asked Questions

Where is the official list of veterinary drug shortages, and is it the same as the human drug shortage list?

No, they are separate. The veterinary drug shortage list is maintained by the FDA Center for Veterinary Medicine (CVM) and can be accessed on the FDA's website. The human drug shortage list is maintained by the FDA Center for Drug Evaluation and Research (CDER). Because veterinarians frequently use human drugs extra-label, a shortage on the human list can directly impact veterinary supply, but the CVM only lists shortages for approved animal drugs.

Can I use a human drug extra-label when the veterinary product is backordered?

Yes, under the Animal Medicinal Drug Use Clarification act (AMDUCA), veterinarians have the legal right to prescribe FDA-approved human drugs extra-label to animal patients under a valid VCPR, provided there is no approved animal drug available that can treat the condition, or if the approved animal drug is clinically ineffective. When the veterinary drug is on backorder and unavailable, utilizing the human equivalent extra-label is a common and legal solution.

How do I report a veterinary drug shortage the FDA does not have listed yet?

Veterinarians, distributors, and clinic staff can report supply disruptions directly to the FDA CVM by emailing AnimalDrugShortages@fda.hhs.gov. Providing the product name, manufacturer, package size, and the specific distribution issues encountered helps the FDA identify emerging national supply failures early.

Sources

Topics
Clinic Workflow & OperationsDrug Safety & Toxicology
Related Articles